CLL patients with a proportion of 1.6% TLR2-positive B CD5+ cells (according to the ROC analysis) or more had a longer time to treatment and longer OS than the group with a lower percentage of TLR2 positive cells. This evidence concerns the gene TLR2 and B-cell chronic lymphocytic leukemia.